I dasatinib- armen opnåede 93% af patienterne CHR inden cross - over og i imatinib- armen opnåede 82% af patienterne CHR inden cross- over.
Ninety-three percent of patients in the dasatinib arm and 82% of patients in the imatinib arm achieved a CHR prior to crossover.